secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2023-07-24T23:59:59+00:00
Accession:  0001193125-23-191895
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta appoints ex-Kite Pharma CCO Shawn Tomasello to board; updates DSG3-CAART data
--------------------------------------------------------------------------------

- Shawn Tomasello, former Kite Pharma CCO, appointed to board effective July 21, 2023.
- Tomasello granted option for 44,000 shares at $13.48, vesting quarterly over three years.
- DSG3-CAART combination sub-study shows modestly increased persistence with cyclophosphamide pretreatment.
- New DSG3-CAART cohort initiated adding fludarabine to regimen to improve engraftment.
- Company reiterates guidance for CABA-201 3-month clinical data by first half of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523191895/0001193125-23-191895-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000119312523191895/d504778d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-191895

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer